Crewe Advisors’s Denali Therapeutics DNLI Stock Holding History

Crewe Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4	Closed	-$119	–	676
2023 Q2	$119	Buy	+4	New	+$112	﹤0.01%	842

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Crewe Advisors's DNLI Position: Q3 2023 in Review

Crewe Advisors sold out of Denali Therapeutics (DNLI) in Q3 2023, closing a stake of 4 shares — an estimated $119 sold.

Crewe Advisors first reported a position in DNLI in Q2 2023 and held it in 1 quarter. The position peaked at $119 in Q2 2023. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

Crewe Advisors reported no remaining Denali Therapeutics position as of Q3 2023 after selling out during the quarter.
Crewe Advisors sold 4 Denali Therapeutics shares in Q3 2023, an estimated $119.
Crewe Advisors first reported a position in Denali Therapeutics in Q2 2023 and held it in 1 quarter.
Crewe Advisors's Denali Therapeutics position peaked at $119 in Q2 2023.
194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on Crewe Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.